Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
研究单位：[1]ADC Therapeutics S.A.[2]University of California San Diego Moores Cancer Center,La Jolla,California,United States,92093[3]Redlands Community Hospital,Redlands,California,United States,92373[4]The Oncology Institute of Hope and Innovation,Whittier,California,United States,90603[5]Baptist MD Anderson Cancer Center,Jacksonville,Florida,United States,32207[6]Norton Cancer Institute,Louisville,Kentucky,United States,40207[7]Comprehensive Cancer Centers of Nevada - Henderson,Las Vegas,Nevada,United States,89169[8]Kaiser Permanente Interstate Medical Office Central,Portland,Oregon,United States,97227[9]Hollings Cancer Center,Charleston,South Carolina,United States,29425[10]Texas Oncology Corporate Office,Dallas,Texas,United States,75251[11]Huntsman Cancer Institute and Hospital,Salt Lake City,Utah,United States,841112[12]Virginia Cancer Specialists,Gainesville,Virginia,United States,20155[13]Medical College of Wisconsin Cancer Center Clinical Trials Office,Milwaukee,Wisconsin,United States,53226[14]Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan,Brugge,Belgium,8000[15]Cliniques Universitaires Saint-Luc,Brussels,Belgium,1200[16]Centre Hospitalier Universitaire Universite Catholique de Louvain,Namur,Belgium,B-5530[17]Algemeen Ziekenhuis Delta - Campus Rumbeke,Roeselare,Belgium,8800[18]Cross Cancer Institute,Edmonton,Canada,T6G 1Z2[19]Research Institute of the McGill University Health Centre,Montréal,Canada,H4A 3J1[20]Hôpital Fleurimont,Sherbrooke,Canada,J1H 5H3[21]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510280[22]Henan Cancer Hospital - Zhengzhou University,Zhengzhou,Henan,China,450008[23]Jilin Cancer Hospital,Changchun,Jilin,China,130021[24]The First Hospital of Jilin University,Changchun,Jilin,China,130021[25]Second Affiliated Hospital of Dalian Medical University,Dalian,Liaoning,China,116000[26]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China,300060[27]Huizhou Municipal Central Hospital,Huizhou,China,516001[28]The First Affiliated Hospital of Nanchang University,Nanchang,China,330006[29]Institute of Hematology and Blood Diseases Hospital of CAMS - PUMC,Tianjin,China,300020[30]Wuhan Union Hospital,Wuhan,China,430023[31]Tongji Hospital,Wuhan,China,430030[32]Fakultni nemocnice Ostrava,Ostrava,Czechia,708 52[33]Fakultni Nemocnice Kralovske Vinohrady,Prague,Czechia,100 34[34]Fakultni nemocnice v Motole,Prague,Czechia,150 06[35]Hôpital Avicenne,Bobigny,France,93000[36]Centre Hospitalier Regional Universitaire Brest,Brest,France,29200[37]CHU Dijon Bourgogne - Hôpital François Mitterrand,Dijon,France,21000[38]Hôpital Privé du Confluent,Nantes,France,44200[39]Hopital Universitaire Pitie Salpetriere,Paris,France,75651[40]Hôpital Haut-Lévêque,Pessac,France,33604[41]Centre de Lutte Contre le Cancer - Centre Henri-Becquerel,Rouen,France,76038[42]Samson Assuta Ashdod University Hospital,Ashdod,Israel,7747629[43]Soroka Medical Center,Be'er Sheva,Israel,8410101[44]Shamir Medical Center (Assaf Harofeh),Be'er Ya'aqov,Israel,7030000[45]Carmel Medical Center,Haifa,Israel,3436212[46]Rabin Medical Center - Beilinson Hospital,Petah tikva,Israel,4941492[47]The Chaim Sheba Medical Center,Tel Aviv,Israel,52621[48]Tel Aviv Sourasky Medical Center,Tel Aviv,Israel,6423906[49]Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia,Brescia,Italy,25123[50]Azienda Ospedaliero - Universitaria Careggi,Florence,Italy,50134[51]Ospedale Casa Sollievo della Sofferenza,Foggia,Italy,71013[52]Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST,Meldola,Italy,47014[53]Istituto Europeo di Oncologia,Milano,Italy,20141[54]Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas,Milan,Italy,20089[55]Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele,Milan,Italy,20132[56]Fondazione IRCCS Policlinico San Matteo,Pavia,Italy,27100[57]Sanitaria Locale della Romagna,Ravenna,Ital
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
